SOHO State of the Art Updates and Next Questions: Measurable Residual Disease in Acute Lymphoblastic Leukemia - Optimization and Innovation in 2022 and Beyond-Reference-Cited by-同舟云学术

SOHO State of the Art Updates and Next Questions: Measurable Residual Disease in Acute Lymphoblastic Leukemia - Optimization and Innovation in 2022 and Beyond

Published:2022-12 Issue:12 Volume:22 Page:878-882
ISSN:2152-2650
Container-title:Clinical Lymphoma Myeloma and Leukemia
language:en
Short-container-title:Clinical Lymphoma Myeloma and Leukemia

Author:

Dekker Simone E.,Leonard Jessica,Muffly Lori

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference33 articles.

1. A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403;Stock;Blood,2019

2. Philadelphia chromosome negative B-cell acute lymphoblastic leukemia in older adults: Current treatment and novel therapies;O'Dwyer;Best Pract Res Clin Haematol,2017

3. Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation;Gokbuget;Blood,2012

4. Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia;Kantarjian;N Engl J Med,2017

5. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase II results of the single-arm, open-label, multicentre ZUMA-3 study;Shah;The Lancet,2021

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Measurable residual disease (MRD)-testing in haematological cancers: A giant leap forward or sideways?;Blood Reviews;2024-08

2. Advances in the treatment of Philadelphia chromosome negative acute lymphoblastic leukemia;Blood Reviews;2024-07

3. Using Measurable Residual Disease to Optimize Management of AML, ALL, and Chronic Myeloid Leukemia;American Society of Clinical Oncology Educational Book;2023-06